Drug Type Synthetic peptide |
Synonyms JSM 6427 |
Target |
Action antagonists |
Mechanism α5β1 antagonists(Integrin alpha-5/beta-1 antagonists) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
License Organization- |
Drug Highest PhaseDiscontinuedPhase 1 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Glycogen Storage Disease Type II | Phase 1 | United States | 01 Sep 2007 | |
Wet age-related macular degeneration | Phase 1 | United States | 01 Sep 2007 | |
Vitreoretinopathy, Proliferative | Preclinical | Germany | 01 May 2007 | |
Retinopathy of Prematurity | Preclinical | Germany | 01 May 2006 |
Phase 1 | - | bnxjjzpnai(oaddlwwqwv) = cmeupfftoj qdozotqeqp (jryddqexrr ) | - | 01 Apr 2009 | |||
Phase 1 | - | mrekxdhyec(pzsfuvszrl) = ngxjruqaxu bszklixllq (cjvbwhkjge ) View more | Positive | 01 May 2008 |